COMMUNIQUÉS West-GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock
08/12/2025
WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
08/12/2025
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“ [...]
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
08/12/2025
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
08/12/2025
BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for [...]
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
08/12/2025
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Kymera Therapeutics Announces Proposed Public Offering
08/12/2025
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
08/12/2025
WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
08/12/2025
WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most [...]
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
08/12/2025
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile maintained with longer [...]
A-Team Home Care Turns Nine and Shines—Earning Philadelphia100 Top-20, Philadelphia Inquirer's Best in Philly Home Care, and 2025 Best Employer & Senior Care Titles in Bucks Happenings
08/12/2025
Marking nearly a decade of service, A-Team Home Care celebrates sweeping regional awards that underscore its impact on clients, caregivers, and the Philadelphia community. Philadelphia, PA , Dec. 08, 2025 (GLOBE [...]
Zelluna ASA - Mandatory notification of trade
08/12/2025
Reference is made to the private placement (the " Private Placement ") and the retail offering through PrimaryBid announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR-form related to share lending [...]
Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
08/12/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Novembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08/12/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Surgery Partners and Baylor Scott & White Health Form Joint Venture to Expand Access to Quality Care
08/12/2025
The Physicians Centre Hospital in Bryan to become a Baylor Scott & White facility, as health system grows to keep up with population increase in the Brazos Valley BRENTWOOD, Tenn., and BRYAN/COLLEGE STATION, Texas, [...]
Nelipak® Acquires Merrill’s Packaging
08/12/2025
Strengthens presence in growing healthcare manufacturing and innovation hubs. CRANSTON, R.I., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nelipak ® Corporation (“Nelipak”), a leading global provider of healthcare packaging [...]
International study offers new path to reduce spinal taps in young infants with fevers
08/12/2025
New evidence from a six-country study led by the Montreal Children’s Hospital and Children’s National Hospital shows simple blood and urine tests could spare many young infants with fevers from more invasive procedures [...]
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
08/12/2025
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate [...]
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
08/12/2025
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 [...]
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
08/12/2025
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not [...]

Pages